Kyntra Bio, Inc. (KYNB) — Cash Flow-to-Debt Ratio
Kyntra Bio, Inc. (KYNB) has a Cash Flow-to-Debt Ratio of -0.04x as of June 2026, meaning its operating cash flow of $-3.99 Million could theoretically repay 0% of its total liabilities ($109.22 Million) in one year. See KYNB financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Kyntra Bio, Inc. Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Kyntra Bio, Inc. across 14 annual periods. For the full cash flow conversion analysis, see KYNB operating cash flow.
Annual Cash Flow-to-Debt Ratio for Kyntra Bio, Inc. (2012–2025)
Year-by-year debt coverage analysis for Kyntra Bio, Inc.. Check how high is Kyntra Bio, Inc.'s earnings quality to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.04x | $-4.77 Million | $115.12 Million | ▲ +88.0% |
| 2024 | -0.35x | $-138.00 Million | $398.16 Million | ▲ +35.6% |
| 2023 | -0.54x | $-315.02 Million | $585.73 Million | ▼ -125.4% |
| 2022 | -0.24x | $-145.93 Million | $611.57 Million | ▼ -58.1% |
| 2021 | -0.15x | $-82.23 Million | $544.71 Million | ▼ -171.3% |
| 2020 | 0.21x | $81.60 Million | $385.39 Million | ▲ +186.6% |
| 2019 | -0.24x | $-78.70 Million | $321.99 Million | ▼ -13.0% |
| 2018 | -0.22x | $-76.14 Million | $352.13 Million | ▼ -2.8% |
| 2017 | -0.21x | $-66.51 Million | $316.20 Million | ▼ -971.4% |
| 2016 | 0.02x | $7.11 Million | $294.44 Million | ▲ +135.6% |
| 2015 | -0.07x | $-18.57 Million | $273.75 Million | ▼ -173.5% |
| 2014 | 0.09x | $22.41 Million | $242.85 Million | ▼ -32.6% |
| 2013 | 0.14x | $25.92 Million | $189.35 Million | ▲ +450.2% |
| 2012 | -0.04x | $-5.61 Million | $143.40 Million | — |